Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-04-20
Target enrollment:
Participant gender:
Summary
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to
determine the safety, tolerability, efficacy, PK of bb2121 in combination with other
therapies in adult subjects with R/RMM.
The following combinations will be
- Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone)
- Arm B will test bb2121 in combination with BMS-986405 (JSMD194)
- Arm C will test bb2121 in combination with one of the following standard triplet
regimens: 1) Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose
dexamethasone (DPd); 2) Pomalidomide (POM) in combination with bortezomib (BTZ) and
low-dose dexamethasone (PVd)
Combination agents being tested may be administered before, concurrently with and/or
following (ie, maintenance) bb2121 infusion.
The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose
expansion may occur in one or more arms.